OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	129
CAR T-cell therapy comes of age: Introductory editorial for the special issue	57
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	38
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	31
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	30
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	28
How to set up a clinical research center in Brazil, as an example of a middle-income country	27
Updates on current and future research in acute myeloid leukemia	27
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	21
Epidemiology and etiology of diffuse large B-cell lymphoma	21
Lessons learned from the Eµ-TCL1 mouse model of CLL	20
Somatic mutations in “benign” blood diseases	18
TET2 mutation as prototypic clonal hematopoiesis lesion	17
Antibody and immunotherapy in diffuse large B-cell lymphoma	17
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	17
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	17
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms	15
The role of viruses in HIV-associated lymphomas	15
More disease-modifying therapies for sickle cell disease: are small molecules and drug repurposing the way forward?	15
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	14
The molecular map of CLL and Richter's syndrome	13
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	13
T-cell engaging antibodies for B-cell lymphomas	13
Developing MRD as an early endpoint for accelerated approval in CLL	12
Vaccinations in patients with chronic lymphocytic leukemia	12

Roadmap for developing MRD as an early endpoint for drug approval in lymphoma	12
Cellular and immunotherapies for myelodysplastic syndromes	11
outside front cover, PMS 8883 metallic AND 4/C	11
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	11
Clonal hematopoiesis	11
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	11
outside front cover, PMS 8883 metallic AND 4/C	10
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	10
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?	10
The biology of classical Hodgkin lymphoma	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
Challenges and opportunities of CAR T-cell therapies for CLL	9
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	9
Engineering the Next Generation of Antibody Therapeutics in Hematology	9
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	9
Menin inhibition for the treatment of acute leukemia	8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
The pediatric approach to Hodgkin lymphoma	8
The crossroads of cancer therapies and clonal hematopoiesis	7
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin	7
Understanding MDS stem cells: Advances and limitations	7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	7
DLBCL arising from indolent lymphomas: How are they different?	7
Somatic compensation of inherited bone marrow failure	7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs	7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
Somatic mutations in acquired pure red cell aplasia	7
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	6
outside front cover, PMS 8883 metallic AND 4/C	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
miRNA Biology in Chronic Lymphocytic Leukemia	6
Measurable residual disease after CAR T-cell therapy	6
Clonal hematopoiesis in telomere biology disorders	6
Diagnosis and Management of Hematologic Malignancies in the Context of Telomere Biology Disorders	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
License for a CAR T: Examining patient eligibility	5
outside front cover, PMS 8883 metallic AND 4/C	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management	5
Special edition of the Seminars in Hematology series on Global Hematology Care	4
The case for prioritizing malignant hematology services in low- and middle-income countries	4
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
Inflammation in myelodysplastic syndrome pathogenesis	4
table of contents (2 pages)	4
AML diagnostics in the 21st century: Use of AI	4
Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies	4
Tuning CAR T-cell therapies for efficacy and reduced toxicity	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4
RNA splicing as a therapeutic target in myelodysplastic syndromes	4
Rare somatic manifestations of telomere biology disorders	3
Genetic aspects of telomere biology disorders	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
outside front cover, PMS 8883 metallic AND 4/C	3
Targeted immunoPET imaging of multiple myeloma	3
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape	3
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	3
Special issue on circulating tumor DNA: Introductory editorial	3
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers	3
Role of the tumor microenvironment in CLL pathogenesis	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
masthead	3
Solid malignancies in telomere biology disorders	3
outside front cover, PMS 8883 metallic AND 4/C	3
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics	3
Applications of virus-specific T cell therapies post-BMT	3
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	3
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	3